bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: M A M F J
2018: D N O S A J J M

 
  Other news for:
Lymphoma
 Resources from HONselect
Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug

By Scott Roberts

WEDNESDAY, Nov. 28, 2018 (HealthDay News) -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday.

A biosimilar is a biological product that is approved based on data showing it is "highly similar" to a drug already approved by the FDA, with no "clinically meaningful differences in terms of safety, purity and potency," the agency said in a news release.

Truxima, as with Rituxan, is approved to treat adults with CD20-positive, B-cell non-Hodgkin's lymphoma. The most common side effects of Truxima are infusion reactions, fever, low blood lymphocytes, chills, infection and weakness.

The drug's label includes a boxed warning that users also may be at increased risk of fatal infusion reactions, severe skin and mouth reactions, reactivation of hepatitis B, and a rare deadly brain infection known as PML.

Users should not receive vaccinations while in treatment with Truxima, the agency warned, adding that women who are pregnant or breastfeeding shouldn't take the drug.

Truxima is produced by the South Korean drugmaker Celltrion. Rituxan, produced by the San Francisco firm Genentech, was approved in 1997.

More information

Visit the FDA to learn more.

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=740085

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Lymphoma
Lymphoma, Non-Hodgkin
Infection
Adult
Brain
Fever
Lymphocytes
Therapeutics
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact